J&J: secures production capacity for potential Covid vaccine

(CercleFinance.com) - Johnson & Johnson said that its Janssen unit is working with life sciences company Emergent BioSolutions to support the manufacture of its investigational COVID-19 vaccine candidate.


Under the terms of the deal, Emergent will reserve operations capacity to potentially support commercial manufacturing for the vaccine beginning in 2021.

J&J said it has already begun preparations for vaccine production at its facility in Leiden, the Netherlands, with the aim of initiating Phase 1 human clinical trials in September.

The US healthcare giant has committed to rapidly produce and supply over one billion doses of its vaccine, which could be available in early 2021.

Copyright (c) 2020 CercleFinance.com. All rights reserved.